drugset / Trial / NCT02648659

The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients

NCT02648659

Phase 4 Completed 50 enrolled Kyungpook National University Hospital
Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study assessed the effect of tailored eradication therapy according to Clarithromycin resistance in Helicobacter pylori patients.

Timeline

Start
2016-03-02
Primary completion
2017-01-06
Completion
2017-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg
Subject Ilaprazole Small molecule 10 mg
Subject Metronidazole Small molecule 500 mg
Background Amoxicillin Other / unclassified 500 mg

Indications